Evidence map›Paper›PMID 41657860›Full record

ArticleInfectious medicine2026

Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report.

Antonio Mastroianni, Valeria Vangeli, Giuliana Guadagnino, Luciana Chidichimo, Lavinia Berardelli, Sonia Greco

Abstract readCase Reports
In one paragraph

Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonio MastroianniInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.
Valeria VangeliInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.
Giuliana GuadagninoInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.
Luciana ChidichimoInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.
Lavinia BerardelliInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.
Sonia GrecoInfectious & Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Annunziata Hub Hospital, Cosenza 87100, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delafloxacin (DLFX), a new anionic fluoroquinolone, has been approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of bacterial skin and skin structure infections and by the FDA for community-acquired pneumonia. This report describes a novel use of DFX as oral monotherapy in the treatment of staphylococcal prosthetic endocarditis. Prospective data would be useful to identify future opportunities for the use of this new fluoroquinolone in endocarditis both as monotherapy and for oral use,to simplify antibiotic regimen and to improve patients' quality of life and adherence to therapy.

Indexed as

DelafloxacinEndocarditisStaphylococcus aureus

Identifiers

PMID41657860
PMCPMC12874571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.